Everest Organics Limited developed Molnupiravir, a new API to treat COVID-I9

Everest Organics Limited today announced the successful development of an anti-viral API 'MOLNUPIRAVIR' an additional COVID-19 treatment drug that is being developed at Lab Scale for the first-line treatment of COVID-19 in adults patients with mild to moderate symptoms.

Dr. Srikakarlapudi Sirisha, Chief Executive Officer, EOL - New Product Development said that "After the successful development and commercialization of various COVID-19 drugs, such as Oseltamivir, Remdesivir, Posaconazole, Everest Organics Limited is on its path of expansion of this portfolio and hence has further developed an additional COVID-19 treatment API in that segment. 'Molnupiravir' is an API that reduces the risk of hospitalization and death by around 50% for patients with mild or moderate cases of Covid. The APl, Molnupiravir is administered orally and works by inhibiting the replication of the coronavirus inside the body. Everest is planning and preparing to be an active player in viral segment in the upcoming future.

Shares of EVEREST ORGANICS LTD. was last trading in BSE at Rs. 300.25 as compared to the previous close of Rs. 300.20. The total number of shares traded during the day was 6788 in over 192 trades.

The stock hit an intraday high of Rs. 307.70 and intraday low of 296.00. The net turnover during the day was Rs. 2033191.00.

Source : Equity Bulls

Keywords

EVERESTORGANICS INE334C01029 Pharmaceuticals Molnupiravir API Covid19Treatment AntiViral